A provision of the summer’s One Big Beautiful Bill Act bumping a slew of orphan drugs from Medicare price negotiation is ...
US Rare Disease Drug Sales Market Opportunity To Surpass USD 190 Billion By 2030 Says Kuick ResearchDelhi, Oct. 16, 2025 ...
The One Big Beautiful Bill Act removed a number of orphan drugs from being subject to price negotiations, and this could cost ...
The Congressional Budget Office said Monday that a provision in the GOP’s reconciliation bill that widened an exemption for ...
Upon Approval of NDA Quoin Will Receive Seven Years Marketing Exclusivity for QRX003 in the USOrphan Drug Designation previously granted by the ...
The Congressional Budget Office says exemptions for orphan drugs as part of Medicare price negotiations will cost taxpayers ...
This article outlines common CMC problems that are obstacles that steal momentum and create costly detours in the development ...
The U.S. Congressional Budget Office said on Monday that new exemptions to drug price negotiations for several blockbuster ...
An unnamed source clarified that Sandra Retzky has not been fired from the FDA, but it remains unclear where she was ...
AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track Designation for AJ201, the first-in-class for therapy for ...
Beam Therapeutics recently announced that its BEAM-302 program received FDA orphan drug designation, alongside encouraging updates for its gene-editing therapies targeting rare diseases such as sickle ...
A local gene therapy pioneer is taking on some of the rarest diseases known to medicine with a new venture spun out from his existing company.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback